Gene expression markers for response to EGFR inhibitor drugs
    4.
    发明申请
    Gene expression markers for response to EGFR inhibitor drugs 审中-公开
    用于EGFR抑制剂药物的基因表达标志物

    公开(公告)号:US20050164218A1

    公开(公告)日:2005-07-28

    申请号:US10857715

    申请日:2004-05-28

    IPC分类号: C12Q1/68

    摘要: The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.

    摘要翻译: 本发明涉及与癌症相关的预后标志物。 特别地,本发明涉及基于石蜡包埋的癌症组织固定样品中基因表达的分子表征的预后方法,其允许医师预测患者是否可能对EGFR抑制剂治疗反应良好。

    Gene expression markers for predicting response to chemotherapy
    8.
    发明申请
    Gene expression markers for predicting response to chemotherapy 有权
    用于预测化疗反应的基因表达标志物

    公开(公告)号:US20050260646A1

    公开(公告)日:2005-11-24

    申请号:US11102228

    申请日:2005-04-07

    IPC分类号: C12Q1/68

    摘要: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

    摘要翻译: 本发明提供了一组基因,其表达在癌症的预后中是重要的。 特别地,本发明提供了可用于预测癌症患者是否可能对化学疗法有有益治疗反应的基因表达信息。 MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; 肝素 AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1,BCL2,ESR1; 或相应的表达产物,所述报告包括所述受试者具有降低的化疗反应可能性的预测。